Arypsa

Arypsa EV/EBIT

EV/EBIT (Enterprise Value to EBIT) of Arypsa (APYI) as of Nov 2, 2026.

EV/EBIT

0.00

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Arypsa is 2008 0.00 . EV/EBIT (Enterprise Value to EBIT) of Arypsa was 2007 - . It decreases by % lower compared to the previous year.

The Arypsa EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2001
0.00 USD
Jan 1, 2002
0.00 USD
Jan 1, 2003
0.00 USD
Jan 1, 2004
0.00 USD
Jan 1, 2005
0.00 USD
Jan 1, 2006
0.00 USD
Jan 1, 2007
0.00 USD
Jan 1, 2008
0.00 USD
The Arypsa EV/EBIT history
YEAREV/EBITYoY
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arypsa Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Arypsa's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Arypsa's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Arypsa's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Arypsa grows earnings faster than its peers.

Arypsa Stock analysis

What does Arypsa do? Aspyra Inc. is an American company based in California that specializes in the development and distribution of medical IT solutions. The history of Aspyra dates back to 1993 when the company was founded as an independent provider of medical imaging technology. In the following years, Aspyra expanded its business model and focused on developing integrated solutions for the healthcare industry. Today, the company offers a wide range of products and services such as RIS, PACS, LIS, and teleradiology systems that are used by hospitals, clinics, and medical practices worldwide. Aspyra also has specialized divisions within the company that focus on specific solutions. One of these divisions is INSIGHT, which specializes in the development of LIS systems. These solutions provide a specialized software platform that simplifies laboratory management and the workflow of medical tests and results. Another important division of Aspyra is the teleradiology department, which transmits specialized medical imaging findings and reports via telecommunication systems from one radiologist to another. This is particularly advantageous in providing care to patients in rural areas or areas with limited healthcare services. Aspyra also offers various software products, including the PACS system, the Radiology Information System (RIS), and the LIS system. The PACS system allows for the capture of medical images and provides them in electronic form, while the RIS system facilitates the management process of radiology departments and administrative processes related to the data. The LIS system, specifically tailored to the needs of laboratories, also supports the creation of contingency reports and better quality assurance. In recent years, Aspyra has also formed partnerships with other companies in the healthcare industry to expand its product portfolio. This includes a recent collaboration with Healthline Networks and First Databank to combine its IT systems with health data and information from third-party specialists. Aspyra has established itself as a leading provider of medical IT solutions and offers its customers a wide range of products and services. Thanks to its expertise in the healthcare industry, the company has been able to expand its presence in the global market and establish itself as an important partner for medical facilities in North America and Europe. Arypsa is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arypsa stock

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Arypsa since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Arypsa with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Arypsa

All Key Metrics — Arypsa